Published in final edited form as:

Bioorg Med Chem Lett. 2011 March 15; 21(6): 1719–1723. doi:10.1016/j.bmcl.2011.01.079.

Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) Inhibitors

Yuanjun He, Theodore M. Kamenecka, Youseung Shin, Xinyi Song, Rong Jiang, Romain Noel, Derek Duckett, Weimin Chen, Yuan Yuan Ling, Michael D. Cameron, Li Lin, Susan Khan, Marcel Koenig*, and Philip V. LoGrasso*

Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458

Quinazoline **3** was discovered as a novel c-jun N-terminal kinase (JNK) inhibitor with good brain penetration and pharmacokinetic (PK) properties. A number of analogs which were potent both in the biochemical and cellular assays were discovered. Quinazoline **13a** was found to be a potent JNK3 inhibitor ($IC_{50} = 40$ nM), with > 500-fold selectivity over p38, and had good PK and brain penetration properties. With these properties, **13a** is considered a potential candidate for *in vivo* evaluation.

c-jun-N-terminal Kinase (JNK) was discovered in the early-mid 1990s^{1–4} and is a member of the mitogen activated protein kinase (MAP) family. In the nearly two decades of work on JNK, the enzyme has been implicated in numerous diseases ranging from cardiovascular disease⁵, to metabolic disorders⁶ and neurodegeneration^{7–11}. There are three isoforms of JNK. JNK1 and JNK2 are ubiquitously expressed, whereas JNK3 is expressed primarily in the brain with lower levels of expression in the heart and testis¹².

Because of the numerous potential clinical applications for JNK, many small molecule inhibitor programs have developed over the past five years. Compound classes that have shown nice JNK selectivity include: aminopyrazoles¹³, aminopyridines^{14, 15}, pyridine carboxamides^{15, 16}, benzothien-2-yl-amides and benzothiazol-2-yl acetonitriles^{17, 18}, quinoline derivatives¹⁹, and aminopyrimidines^{20–22}. For a recent review of all these classes see LoGrasso and Kamenecka²³. Most of these classes of compounds did not demonstrate good brain penetration, although Kamenecka et al. recently reported aminopyrimidines showing excellent brain penetration properties²².

In the current work we present a series of novel quinazolines which were potent JNK inhibitors with > 2200-fold selectivity over p38 (compound **14d**). Moreover, a systematic SAR approach utilizing biochemical and cell-based assays, along with mouse and rat pharmacokinetics enabled us to develop compounds (e.g. **13a**) which maintained their potency and selectivity (> 500-fold over p38), while also incorporating good brain penetration (brain: plasma ratio of 0.8:1) in mouse, and excellent pharmacokinetics in rat. With these properties, **13a** is an attractive candidate for *in vivo* evaluation in CNS efficacy models.

© 2011 Elsevier Ltd. All rights reserved.

*To whom correspondence should be addressed: Phone: 561-228-2230; Fax: 561-228-3081 (P.L.); Phone: 561-228-2212 (M.K.); lograsso@scripps.edu; marcelk@scripps.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The JNK inhibitors **1a,b** and **2** (figure 1) were described in the patent and primary literature, ^{22, 24} with JNK3 IC₅₀ = 90 nM for **1b** and IC₅₀ = 180 nM for **2** respectively ^{22,25}. The isoquinoline **1b** was only moderately potent in cells however (inhibition of c-jun phosphorylation = 1.0 μM). Compounds **1b** and **2** were found to have good brain penetration and PK properties^{22,24}. As a strategy to design a novel structural class with improved JNK3 potency and similar or improved PK and brain penetration properties, we decided to combine the amino isoquinoline of compound **1** and the amino pyrimidine scaffolds (compound **2**). With this in mind we designed quinazoline **3** (Figure 1). We found that quinazoline **3** was a potent JNK inhibitor with good brain penetration (Table 1). To establish an SAR on the quinazoline ring, we first modified the 7-position (Table 1). The synthesis is outlined in scheme 1. For the syntheses of the 2-chloro quinazolines from the corresponding fluoro aldehydes we followed the procedure described by Patel et al.²⁶ A series of pyrazole, isoxazole, morpholino, and pyridyl substitutions were assessed at the 7-position on the quinazoline ring (compounds **3-8f**, Table 1). Pyrazole substitutions (compounds **3, 8a, 8g, 8h**) had the lowest JNK3 IC₅₀ values, suggesting preference for pyrazole at the 7-position (Table 1). Despite the approximate 3-fold improvement in cell-based potency of **8a** over **3**, the higher polar surface area of **8a** caused a significant decrease in brain penetration (Table 1). The available space for modifications in this position appeared to be very limited and we concluded that the *N*-methyl-pyrazole moiety was optimal in terms of overall properties. Replacement of the 3-morpholino on the 1,2,4-triazole (**8a**) with 3-*p*-methyl-pyridyl on the 1,2,4-triazole (**8g**) decreased the cell-based IC₅₀ by 3-fold to 40nM. However, this substitution caused brain penetration to be quite poor (**8h**) (Table 1), especially when compared to compound **3**. Attempts to improve the potency and maintain the good pharmacological profile by replacing the morpholino-triazolo aniline moiety were unsuccessful (data not shown).

We next investigated the 8-position on the quinazoline ring (Table 2). We found a number of different substitutions that improved the biochemical potency. Compound **9a** showed good cellular potency but unfortunately the brain penetration was poor (Table 2). Similarly, the thiazole replacement at position 8 improved the JNK3 potency by 4-fold (compare **9d** to **9a**), but the cell-based IC₅₀ for **9d** was 150-fold less potent than **9a** suggesting decreased cell penetration for **9d**. By replacing the methyl pyridine group with phenyl groups and thus reducing the polar surface area we indeed did achieve much improved brain penetration (compounds **9e/f**), but unfortunately these compounds were only modestly active in cells (Table 2). Compound **9g** did have both good brain penetration and potency (Table 2); however the PK properties were poor (data not shown).

In an effort to improve the brain penetration and also PK properties of **9a** we further explored the effect of substitutions in the 2-position (Table 3). We hypothesized that by introducing groups in the 2-position that would reduce the polar surface area and molecular weight we would improve the brain penetration. Compound **10b** indeed showed much improved brain to plasma ratio compared to **9a**; however the plasma concentration was low presumably due to high clearance. Furthermore, the good biochemical potency did not translate into good cellular potency (Table 3). Despite extensive synthetic efforts we were unable to achieve the good PK and brain penetration properties we had with quinazoline **3** by modifying the 2-, 7- and 8- positions. Generally, the 8-substituted quinazolines led to more potent compounds but poorer PK properties. A contributing factor may be the significantly shorter half lives in microsomes as compared to the 7-substituted analogs. It became apparent that compounds with the *N*-methyl pyrazole group in the 7-position led to compounds with good pharmacological properties and substitutions in the 8-position improved the potency. We should also note that substitutions in the 5- and 6-positions were generally not well tolerated (data not shown). We therefore focused on the synthesis of analogs bearing the *N*-methyl pyrazole group in the 7-position and different substitutions in

the 8-position (Table 4). All compounds shown in Table 4 were synthesized as outlined in scheme 2, except for compounds **14b** and **14f**, which were made in five steps starting from formylation of 3-fluoro-2-(trifluoromethyl)bromobenzene and 2-bromo-6-fluoroanisole respectively. Compound **14d** showed the best JNK3 potency with $IC_{50} = 9$ nM and cell-based $IC_{50} = 40$ nM, and had great selectivity over p38 ($IC_{50} > 20$ μ M), but unfortunately had very poor brain penetration (Table 4). The great selectivity of compound **14d** for JNK3 over p38 can potentially be attributed to a better fit in the smaller active site for JNK3 and/or a planar structure to the molecule. Compound **14f** was found to be very potent ($IC_{50} = 4$ nM vs JNK3) with good brain penetration; however its oral bio-availability was low (%F = 8) and therefore not a good candidate for further advancement. The same was true for many of the other compounds with good brain penetration in the **14** series. We decided to introduce a chloro substitution at position 8 on the quinazoline ring and identified compound **13a**, which had excellent brain penetration and good PK properties as well (Table 4 and Table 5). Moreover, the compound had > 500-fold selectivity over p38. Compound **13b** had a superior brain:plasma ratio of 1.7:1 compared to **13a**, but suffered from a 6-fold less potent cell-based activity compared to **13a** (Table 4). The PK properties of compounds **3** and **13a** are summarized in Table 5. Compound **13a** is currently under further investigation in animal models.

In summary, we discovered a series of novel quinazoline compounds as JNK inhibitors with good potency in biochemical and cellular assays. Compound **13** improved upon compound **3** by 3-fold in cell potency and had 80% brain penetration compared to 40% for compound **3**. In contrast, compound **3** had a greater systemic exposure and oral bioavailability suggesting that compound **3** may be preferred for non-central nervous system (CNS) indications and compound **13** may be preferred for CNS indications.

Acknowledgments

This work was supported by NIH grant U01NS057153 awarded to P.L.

References and Notes

1. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis R. J. Cell 1994;76:1025.
2. Hibi M, Lin A, Smeal T, Minden A, Karin M. Genes Dev 1993;7:2135. [PubMed: 8224842]
3. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR. Nature 1994;369:156. [PubMed: 8177321]
4. Mohit AA, Martin JH, Miller CA. Neuron 1995;14:67. [PubMed: 7826642]
5. Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, Vitte PA, Gotteland JP, Cirillo R. Br J Pharmacol 2004;142:953. [PubMed: 15210584]
6. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. Nature 2002;420:333. [PubMed: 12447443]
7. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J, Bonny C. Nat Med 2003;9:1180. [PubMed: 12937412]
8. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA. Proc Natl Acad Sci U S A 2004;101:665. [PubMed: 14704277]
9. Carboni S, Antonsson B, Gaillard P, Gotteland JP, Gillon JY, Vitte PA. J Neurochem 2005;92:1054. [PubMed: 15715656]
10. Carboni S, Boschert U, Gaillard P, Gotteland JP, Gillon JY, Vitte PA. Br J Pharmacol 2008;153:157. [PubMed: 18026128]
11. Carboni S, Hiver A, Szyndralewicz C, Gaillard P, Gotteland JP, Vitte PA. J Pharmacol Exp Ther 2004;310:25. [PubMed: 14988419]
12. Martin JH, Mohit AA, Miller CA. Brain Res Mol Brain Res 1996;35:47. [PubMed: 8717339]

13. Kamenecka T, Habel J, Duckett D, Chen W, Ling YY, Frackowiak B, Jiang R, Shin Y, Song X, LoGrasso P. *J Biol Chem* 2009;284:12853. [PubMed: 19261605]
14. Swahn BM, Xue Y, Arzel E, Kallin E, Magnus A, Plobeck N, Viklund J. *Bioorg Med Chem Lett* 2006;16:1397. [PubMed: 16337120]
15. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ, Haasch DL, Wang S, Clampit JE, Johnson EF, Lubben TH, Stashko MA, Olejniczak ET, Sun C, Dorwin SA, Haskins K, Abad-Zapatero C, Fry EH, Hutchins CW, Sham HL, Rondinone CM, Trevillyan JM. *J Med Chem* 2006;49:3563. [PubMed: 16759099]
16. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G. *J Med Chem* 2006;49:4455. [PubMed: 16854050]
17. Angell RM, Atkinson FL, Brown MJ, Chuang TT, Christopher JA, Cichy-Knight M, Dunn AK, Hightower KE, Malkakorpi S, Musgrave JR, Neu M, Rowland P, Shea RL, Smith JL, Somers DO, Thomas SA, Thompson G, Wang R. *Bioorg Med Chem Lett* 2007;17:1296. [PubMed: 17194588]
18. Gaillard P, Jeanclaude-Etter I, Ardisson V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D, Halazy S, Nichols A, Szyndralewicz C, Vitte PA, Gotteland JP. *J Med Chem* 2005;48:4596. [PubMed: 15999997]
19. Jiang R, Duckett D, Chen W, Habel J, Ling YY, LoGrasso P, Kamenecka TM. *Bioorg Med Chem Lett* 2007;17:6378. [PubMed: 17911023]
20. Alam M, Beevers RE, Ceska T, Davenport RJ, Dickson KM, Fortunato M, Gowers L, Haughan AF, James LA, Jones MW, Kinsella N, Lowe C, Meissner JW, Nicolas AL, Perry BG, Phillips DJ, Pitt WR, Platt A, Ratcliffe AJ, Sharpe A, Tait LJ. *Bioorg Med Chem Lett* 2007;17:3463. [PubMed: 17459703]
21. Humphries PS, Lafontaine JA, Agree CS, Alexander D, Chen P, Do QQ, Li LY, Lunney EA, Rajapakse RJ, Siegel K, Timofeevski SL, Wang T, Wilhite DM. *Bioorg Med Chem Lett* 2009;19:2099. [PubMed: 19327989]
22. Kamenecka T, Jiang R, Song X, Duckett D, Chen W, Ling YY, Habel J, Laughlin JD, Chambers J, Figuera-Losada M, Cameron MD, Lin L, Ruiz CH, LoGrasso PV. *J. Med. Chem* 2010;53:419. [PubMed: 19947601]
23. LoGrasso P, Kamenecka T. *Mini Rev Med Chem* 2008;8:755. [PubMed: 18673131]
24. Huang, LLS.; Lunney, EA.; Planken, SP. WO 2007/125405. 2007.
25. The biochemical and cellular potency as well as the PK properties and brain penetration of all compounds (including the reference compounds 1a, 1b and 2) were tested at Scripps Florida. The biochemical IC50s for JNK1 and JNK3 were determined using HTRF. Briefly, final assay concentrations of JNK1, JNK3, biotinylated-ATF2 and ATP were 0.1 nM, 0.3 nM, 0.4 nM and 1 mM respectively. In each assay the phosphor-Thr71-ATF-2 product was detected using Europium-cryptate labeled anti-phospho-THR71-ATF-2 antibody. Streptavidin-allophycocyanin-XL was used as the acceptor. A 10-point dose-response curve for each compound was generated in duplicate and data was fit to a four parameter logistic. See Reference ¹⁹ for details of cell-based assays.
26. Patel, VFKJL.; Geuns-Meyer, SD.; Chaffee, SC.; Cee, VJ.; Hodous, BL.; Bellon, S.; Harmange, J-C.; Olivieri, PR.; Thaman, MC.; Dimauro, EF.; Buchanan, JL.; McGowan, DC.; Albrecht, BK.; Deak, HL.; Bemis, JE.; White, R.; Martin, MW.; Habgood, GJ.; Tempest, PA.; Masse, CE.; Buckner, WH.; Herberich, BJ.; Graceffa, R.; Zhang, D.; Xu, S.; Sham, K.; Rzasa, RM.; Falsey, JR.; Chakrabarti, PP.; Cao, G-Q.; Tomlinson, SA.; Pettus, LH.; Smith, LA.; Paras, NA.; Liu, G.; Demorin, FF.; Tasker, A.; Reed, A. WO 2006/039718. 2006.

Figure 1.
JNK3 Inhibitors

Scheme 1.

Reagents and conditions: (a) HCl in EtOH, n-BuOH, 120 °C, 2–24 h; (b) Boronic acid, Pd(PPh₃)₄, Na₂CO₃, Dioxane/water, 120 °C, 30', μW.

Scheme 2.

Reagents and conditions: (a) HCl in EtOH, n-BuOH, 120 °C, 2–24 h; (b) Boronic acid, Pd(PPh₃)₄, Na₂CO₃, Dioxane/water, 120 °C, 30', μW; (c) Boronic acid, Pd(PPh₃)₄, Na₂CO₃, Dioxane/water, 100–140 °C 12–16h, μW.

Table 1

Biochemical and Cell-based IC₅₀ Values, and Mouse Plasma and Brain levels for a series of 2,7-substituted quinazolines^a

compound	R'	R	JNK3 IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	b _{mouse} [plasma]	(μM) [brain]
			0.09	0.05	0.31	17.8	7.17
3							
8a			0.05	0.04	0.12	42.9	1.31
8b			0.7	nt	nt	nt	nt

compound	R'	R	JNK3 IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	b _{mouse} [plasma]	(μM) [brain]
8c			4.4	nt	nt	nt	nt

compound	R'	R	JNK3 IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-Jun IC ₅₀ (μM)	b _{mouse} [plasma]	(μM) [brain]
8d			0.21	nt	nt	26.7	8.1

compound	R'	R	JNK3 IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-Jun IC ₅₀ (μM)	b _{mouse} [plasma]	(μM) [brain]
8e			0.73	nt	nt	nt	nt

compound	R'	R	JNK3 IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	b _{mouse} [plasma]	(μM) [brain]
8f			>20	nt	nt	nt	nt

compound	R'	R	JNK3 IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	b _{mouse} [plasma]	(μM) [brain]
8g			0.05	nt	0.04	nt	nt

compound	R'	R	JNK3 IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-Jun IC ₅₀ (μM)	b _{mouse} [plasma]	(μM) [brain]
8h			0.06	0.1	0.29	13.1	1.37

^a JNK3 biochemical IC₅₀ values are the averages of four or more experiments, and the JNK1 and cell-based IC₅₀ values are the averages of two or more experiments. All standard deviations are ≤44% for the biochemical and ≤81 % for the cell-based assays.

^b 10 mg/kg ip 2h.

nt = not tested.

Table 2

Biochemical and Cell-based IC₅₀ Values, and Mouse Plasma and Brain levels for a series of 2,8-substituted quinazolines^a

Compound	R'	R	JNK3M IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	b _{mouse} [plasma]	[μM] [brain]
9a			0.03	0.02	0.02	2.7	0.15
9b			0.02	0.01	0.33	2.2	0.23

Compound	R'	R	JNK3M IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-Jun IC ₅₀ (μM)	b _{mouse} [plasma]	[μM] [brain]
9c			0.07	0.09	0.25	6.1	1.5
9d			0.007	0.03	3.0	nt	nt
9e			0.06	0.05	1.4	5.2	12.7

Compound	R'	R	JNK3M IC ₅₀ (μM)	JNK1 IC ₅₀ (μM)	c-Jun IC ₅₀ (μM)	b _{mouse} [plasma]	[μM] [brain]
9f			0.08	nt	0.5	10.3	7.6
9g			0.02	0.01	0.2	5.0	4.5

Compound	R'	R	JNK3M IC ₅₀ (μ M)	JNK1 IC ₅₀ (μ M)	c-Jun IC ₅₀ (μ M)	<i>b</i> _{mouse} [plasma]	[μ M] [brain]
9h			0.09	nt	5.1	nt	nt

^aJNK3 biochemical IC₅₀ values are the averages of four or more experiments, and the JNK1 and cell-based IC₅₀ values are the averages of two or more experiments. All standard deviations are $\leq 44\%$ for the biochemical and $\leq 81\%$ for the cell-based assays.

^b10 mg/kg ip 2h.

nt = not tested.

Biochemical and Cell-based IC₅₀ Values, and Mouse Plasma and Brain Concentrations for 2-position Substitutions Designed to Reduce Polar Surface Area and Molecular Weight^a

Table 3

compound	R	JNK3 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	b polar surface area	c _{mouse} [plasma]	[μM] [brain]
9a		0.03	0.02	90	2.72	0.15
10a		0.03	nt	77	2.31	0.23
10b		0.06	0.63	68	0.78	1.06
10c		0.17	nt	49	nt	nt

compound	R	JNK3 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	<i>b</i> polar surface area	<i>c</i> _{mouse} [plasma]	[μM] [brain]
10d		0.09	nt	79	0	0
10e		0.05	0.93	69	nt	nt
10f		0.03	3.0	69	nt	nt

^aJNK3 biochemical IC₅₀ values are the averages of four or more experiments, and the JNK1 and cell-based IC₅₀ values are the averages of two or more experiments. All standard deviations are ≤44 % for the biochemical and ≤81 % for the cell-based assays.

^bPolar surface area calculated by ChemBioDraw Ultra 11.0.

10 mg/kg ip 2h,
c

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table 4

Biochemical and Cell-based IC₅₀ Values, and Mouse Plasma and Brain levels for a series of 2,7,8-substituted quinazolines^a

compound	R	R'	JNK3 IC ₅₀ (μM)	c-jun IC ₅₀ (μM)	<i>b</i> _{mouse} [plasma]	[μM] [brain]
13a	Cl	CH ₃	0.04	0.10	10.4	8.3
13b	Cl		0.063	0.62	4.3	7.2
14a	CH ₃	CH ₃	0.01	0.16	7.4	7.6
14b	CF ₃	CH ₃	0.19	nt	8.3	5.6
14c		CH ₃	0.02	0.13	10.6	5.0
14d		CH ₃	0.009	0.04	6.3	0.22
14e		CH ₃	0.01	0.04	6.4	1.1
14f	OMe	CH ₃	0.004	0.05	9.4	4.9

^aThe JNK3 biochemical IC₅₀ values are the averages of four or more experiments, the JNK1 and cell-based IC₅₀ values are the averages of two or more experiments. All standard deviations are ≤44 % for the biochemical and ≤81 % for the cell-based assays.

^b 10 mg/kg ip 2h.

nt = not tested.

Table 5

PK properties of the two lead compounds

compound	<i>a</i> -rat pk				<i>b</i> -mouse	
	Clp (mL/ min/kg)	t _{1/2} (h)	Vd (L/kg)	oral AUC (μM [#] h)	oral Cmax (μM)	%F
3	3	3	0.8	6.3	0.7	28
13a	6	3	1.4	2.3	0.3	19
						17.8
						10.4
						7.2
						8.3

a 1 mg/kg IV, 2 mg/kg po;*b* 10 mg/kg ip 2h.